Literature DB >> 11915029

Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.

Hitoshi Yoshiji1, Shigeki Kuriyama, Junichi Yoshii, Yasuhide Ikenaka, Ryuichi Noguchi, Daniel J Hicklin, James Huber, Toshiya Nakatani, Hirohisa Tsujinoue, Koji Yanase, Hiroo Imazu, Hiroshi Fukui.   

Abstract

The growth of any solid tumor depends on angiogenesis. Among the known angiogenic factors, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), are potent and representative factors involved in tumor development. It has been reported that bFGF and VEGF showed a synergistic effect in both in vitro and in vivo angiogenesis. However, the interaction of these factors on tumor development and angiogenesis, including hepatocellular carcinoma (HCC), has not yet been elucidated. In this study, we examined the combined effect of bFGF and VEGF overexpression by means of a combination of a retroviral tetracycline (tet)-regulated (Retro-Tet) gene expression system, which can manipulate the gene expression in vivo by providing tet in the drinking water, and a conventional plasmid gene expression system. In an allograft study, bFGF and VEGF overexpression synergistically increased tumor growth and angiogenesis in the murine HCC cells. This synergistic effect also was found in established tumors. VEGF messenger RNA (mRNA) expression in the tumor was increased 3.1-fold by bFGF-overexpression, and the bFGF-induced tumor development was significantly attenuated by treatment with KDR/Flk-1 neutralizing monoclonal antibody. In conclusion, these results suggest that bFGF synergistically augments VEGF-mediated HCC development and angiogenesis at least partly by induction of VEGF through KDR/Flk-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11915029     DOI: 10.1053/jhep.2002.32541

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

1.  Modulation of VEGF/Flk-1 receptor expression in the rat pituitary GH3 cell line by growth factors.

Authors:  Matilde Lombardero; Sergio Vidal; Robert Hurta; Alba Román; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 2.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 3.  Cancer gene discovery in hepatocellular carcinoma.

Authors:  Lars Zender; Augusto Villanueva; Victoria Tovar; Daniela Sia; Derek Y Chiang; Josep M Llovet
Journal:  J Hepatol       Date:  2010-03-20       Impact factor: 25.083

4.  A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  John K Chan; Wei Deng; Robert V Higgins; Krishnansu S Tewari; Albert J Bonebrake; Michael Hicks; Stephanie Gaillard; Pedro T Ramirez; Weldon Chafe; Bradley J Monk; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2017-07-18       Impact factor: 5.482

5.  Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.

Authors:  H Yoshiji; S Kuriyama; J Yoshii; Y Ikenaka; R Noguchi; D J Hicklin; Y Wu; K Yanase; T Namisaki; M Yamazaki; H Tsujinoue; H Imazu; T Masaki; H Fukui
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

6.  Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Kosuke Kaji; Yasuhide Ikenaka; Yusaku Shirai; Tadashi Namisaki; Mitsuteru Kitade; Tatsuhiro Tsujimoto; Hideto Kawaratani; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2009-11-26       Impact factor: 7.527

Review 7.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice.

Authors:  Lu Wang; Wei-Zhong Wu; Hui-Chuan Sun; Xiao-Feng Wu; Lun-Xiu Qin; Yin-Kun Liu; Kang-Da Liu; Zhao-You Tang
Journal:  J Gastrointest Surg       Date:  2003 Jul-Aug       Impact factor: 3.452

9.  Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Tadashi Namisaki; Kei Moriya; Mitsuteru Kitade; Yosuke Aihara; Akitoshi Douhara; Hideto Kawaratani; Norihisa Nishimura; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2013-11-07       Impact factor: 7.527

10.  The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus.

Authors:  Zu-Bing Chen; Shi-Qiang Shen; You-Ming Ding; Wei-Xing Wang; Jian-Ping Tao; Li-Jian Liang; Wen-Jie Hu
Journal:  Med Oncol       Date:  2008-12-11       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.